Huabio Rabbit Monoclonal Antibody Development Using B-cell Technology
Huabio has developed a rabbit monoclonal antibody discovery and production platform utilizing optimized rabbit B-cell culture methods. This advanced technique employs rabbits as immunization hosts, combined with proprietary optimized in vitro B-cell culture and high-throughput screening technologies, to identify antigen-specific positive B-cell clones. Selected positive clones are subsequently cloned into expression vectors through SLICE recombinant technology for recombinant antibody production.
Rabbit Monoclonal Antibody Development Service
| Stage | Service Details | Deliverables | Timeline |
|---|---|---|---|
| Antigen Preparation | Antigen provided by client; services and analysis initiated upon project confirmation. | / | / |
| Immunoassay | Free ELISA testing of serum titers; frequency and scheduling of ELISA tests based on client needs. Small volume blood samples tested for antibody titer evaluation. Criteria for positive results: titer ≥ 1:64,000, effective OD value >0.6. | 1) Variable region sequences and corresponding reports for 2 antibody clones. | 8–12 weeks |
| B-cell Screening and Supernatant Collection |
Isolation of rabbit peripheral blood, extraction and plating of B-cells; each rabbit contributes
approximately 1–1.5 mg of recombinant antibody. Supernatants from rabbit B-cell clones are screened by ELISA, and around 10 positive B-cell clones are selected for sequencing. |
2) 1–1.5 mg per recombinant antibody from 2 clones. 2) Comprehensive project report. |
4–6 weeks |
| Recombinant Antibody Production | Confirmed antibody sequences from clients are synthesized and prepared on a larger scale for antibody staining production. Purified antibodies undergo affinity purification via Protein A, followed by buffer exchange, finalized into PBS as the buffer. | / | 4 weeks |